• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

界定并衡量艾滋病流行对商业公司造成的成本。

Defining and measuring the costs of the HIV epidemic to business firms.

作者信息

Farnham P G

机构信息

Centers for Disease Control and Prevention, Atlanta, GA.

出版信息

Public Health Rep. 1994 May-Jun;109(3):311-8.

PMID:8190854
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1403495/
Abstract

Most published estimates of the costs of the epidemic of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) have been developed from the societal perspective, attempting to measure the burden of the epidemic to society in this country. Although societal cost analysis is well-developed, relatively little is known about many of the factors influencing the costs of the epidemic to business firms. The business community may bear a substantial portion of those costs in the form of health-related benefits provided to workers. Other effects of the epidemic in the workplace are related to fears and stigma associated with the illness. The author compares frameworks for analyzing the costs of the epidemic to the business community and to society. Societal costs include direct costs, the resources used in providing health care, and indirect costs, the resources lost to society as a result of the epidemic. Costs to business include illness-based employment costs, legal or administrative costs, prevention costs, perception-based employment costs, care giver costs, and nonmonetary costs. Not all societal costs are borne by business, and businesses may incur costs that are not traditionally measured from the societal perspective.

摘要

大多数已发表的关于人类免疫缺陷病毒(HIV)感染和获得性免疫缺陷综合征(AIDS)流行成本的估计都是从社会角度得出的,试图衡量这种流行病对本国社会的负担。尽管社会成本分析已经很成熟,但对于许多影响企业层面流行病成本的因素,我们了解得相对较少。商业界可能会以向员工提供与健康相关福利的形式承担这些成本的很大一部分。这种流行病在工作场所的其他影响与对这种疾病的恐惧和污名化有关。作者比较了分析这种流行病对商业界和社会成本的框架。社会成本包括直接成本,即提供医疗保健所使用的资源,以及间接成本,即由于这种流行病而使社会损失的资源。企业成本包括因病产生的就业成本、法律或行政成本、预防成本、基于认知的就业成本、护理人员成本和非货币成本。并非所有社会成本都由企业承担,而且企业可能会产生一些传统上不从社会角度衡量的成本。

相似文献

1
Defining and measuring the costs of the HIV epidemic to business firms.界定并衡量艾滋病流行对商业公司造成的成本。
Public Health Rep. 1994 May-Jun;109(3):311-8.
2
AIDS is your business.艾滋病与你息息相关。
Harv Bus Rev. 2003 Feb;81(2):80-7, 125.
3
Knowledge, attitudes, beliefs, and behaviors of the business community relative to HIV-AIDS.商业界对艾滋病毒/艾滋病的知识、态度、信念和行为。
Public Health Rep. 1991 Nov-Dec;106(6):663-6.
4
Costs to business for an HIV-infected worker.
Inquiry. 1994 Spring;31(1):76-88.
5
The private sector and HIV/AIDS in Africa: taking stock of 6 years of applied research.非洲的私营部门与艾滋病毒/艾滋病:对六年应用研究的评估
AIDS. 2007 Jul;21 Suppl 3:S41-51. doi: 10.1097/01.aids.0000279693.61652.2d.
6
Economic costs to business of the HIV/AIDS epidemic.艾滋病流行给企业带来的经济成本。
Pharmacoeconomics. 2004;22(18):1181-94. doi: 10.2165/00019053-200422180-00003.
7
Assessing business responses to HIV / AIDS in Kenya.评估肯尼亚企业对艾滋病毒/艾滋病的应对措施。
AIDS STD Health Promot Exch. 1995(2):13-5.
8
Forecasting the medical care costs of the HIV epidemic: 1991-1994.预测艾滋病流行的医疗费用:1991 - 1994年
Inquiry. 1991 Fall;28(3):213-25.
9
Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.职业性接触艾滋病毒后化学预防的成本效益
Arch Intern Med. 1997 Sep 22;157(17):1972-80.
10
The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.总统2007财年在美国扩大人类免疫缺陷病毒咨询与检测的倡议:对其覆盖范围、影响及成本效益的情景分析
J Public Health Manag Pract. 2007 May-Jun;13(3):239-43. doi: 10.1097/01.PHH.0000267681.00659.e5.

引用本文的文献

1
Methods for Estimating Avoidable Costs of Excessive Alcohol Consumption.估算过度饮酒可避免成本的方法。
Int J Environ Res Public Health. 2021 May 7;18(9):4964. doi: 10.3390/ijerph18094964.
2
Economic costs to business of the HIV/AIDS epidemic.艾滋病流行给企业带来的经济成本。
Pharmacoeconomics. 2004;22(18):1181-94. doi: 10.2165/00019053-200422180-00003.
3
Current controversies in the treatment of HIV infection and AIDS. An economic perspective.HIV感染与艾滋病治疗中的当前争议:经济学视角
Pharmacoeconomics. 1996 Aug;10(2):105-8. doi: 10.2165/00019053-199610020-00001.
4
The economic costs of caring for people with HIV infection and AIDS in England and Wales.在英格兰和威尔士照顾艾滋病毒感染者及艾滋病患者的经济成本。
Pharmacoeconomics. 1996 Apr;9(4):332-40. doi: 10.2165/00019053-199609040-00006.

本文引用的文献

1
The economic costs of illness: a replication and update.疾病的经济成本:一项重复研究与更新
Health Care Financ Rev. 1985 Fall;7(1):61-80.
2
Conceptual issues in assessing the economic effects of the HIV epidemic.
Health Policy. 1989;11(2):105-13. doi: 10.1016/0168-8510(89)90030-4.
3
The lifetime cost of treating a person with HIV.治疗一名艾滋病毒感染者的终身费用。
JAMA. 1993 Jul 28;270(4):474-8.
4
The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States.美国首例10000例获得性免疫缺陷综合征的经济影响。
JAMA. 1986 Jan 10;255(2):209-11.
5
The provision and financing of medical care for AIDS patients in US public and private teaching hospitals.美国公立和私立教学医院为艾滋病患者提供医疗服务及资金支持的情况。
JAMA. 1987 Sep 11;258(10):1343-6.
6
The economic impact of AIDS in the United States.艾滋病在美国造成的经济影响。
Science. 1988 Feb 5;239(4840):604-10. doi: 10.1126/science.3277273.
7
The economic impact of AIDS in the United States.
Health Aff (Millwood). 1988 Fall;7(4):32-45. doi: 10.1377/hlthaff.7.4.32.
8
Selling health promotion to corporate America: uses and abuses of the economic argument.
Health Educ Q. 1987 Spring;14(1):39-55. doi: 10.1177/109019818701400106.
9
Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991.1985年、1986年及1991年美国获得性免疫缺陷综合征的直接和间接成本估计
Public Health Rep. 1987 Jan-Feb;102(1):5-17.
10
The costs of AIDS: a review of the estimates.
Health Aff (Millwood). 1987 Summer;6(2):5-21. doi: 10.1377/hlthaff.6.2.5.